Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514736 | 1.00 | PARP10 (0.53) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL7920173 | 0.96 | PARP10 (0.53) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL30003712 | 0.96 | PARP10 (0.53) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL28004728 | 0.93 | PARP10 (0.47) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL163925 | 0.88 | PARP10 (0.56) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL29429928 | 0.88 | PARP10 (0.56) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL28041457 | 0.83 | MAOA (0.56) | HSD17B10KDM4ECYP2A6MAOAMAOB | |
| Methylamine SCHEMBL27811293 | 0.82 | PARP10 (0.51) | PARP10PARP11HSD17B10KDM4ECYP2A6 | |
| SCHEMBL29501042 | 0.78 | PARP1 (0.55) | PARP10PARP11KDM4ECYP2A6MAOA | |
| SCHEMBL1151194 | 0.78 | PARP1 (0.55) | PARP10PARP11KDM4ECYP2A6MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | SERENEX, INC. | 2008-03-20 | — | — | US | claimed |
| EP-4739672-A1 | NEW COMPOUNDS | Aston University (GB) | 2026-05-13 | — | — | EP | disclosed |
| US-12448363-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4567032-A1 | KIF18A INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| CN-115867346-B | Kinase inhibitors | GB005股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2025008626-A1 | NEW COMPOUNDS | ASTON UNIVERSITY (GB) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024240240-A1 | IMIDAZOLE DERIVATIVES, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-117263948-B | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-0456133-A1 | Hydrazones | CIBA-GEIGY AG (CH) | 1991-11-13 | — | — | EP | disclosed |
| US-5061795-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
| EP-0395734-A4 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | — | 1991-01-02 | — | — | EP | disclosed |
| EP-0395734-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0135177-B1 | BENZOCYCLOALKANE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1989-12-06 | — | — | EP | disclosed |
| EP-0325963-A1 | 1-Aminomethyl-1,2,3,4-tetrahydronaphthalenes and -indanes | ABBOTT LABORATORIES (US) | 1989-08-02 | — | — | EP | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4777257-A | CARDIOVASCULAR DISORDERS | DAIICHI SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4665188-A | Certain [(1-imidazolyl)-lower-alkylene]-tetrahydronaphthalenecarboxylic acids or corresponding idan-carboxylic acids which are thromboxane A2 | DAIICHI SEIYAKU CO., LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| EP-0135177-A2 | Benzocycloalkane derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448363-B2 | Kinase inhibitors | BTK, ABL1, LYN | PARP10 732/4885PARP11 698/4885HSD17B10 4212/4885 |
| US-20080070918-A1 | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives | QDPR, CCND2, CCND1 | PARP10 1765/4885PARP11 1855/4885HSD17B10 355/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | PARP10 565/4885PARP11 288/4885HSD17B10 2728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.